Applied DNA Announces CertainT Platform Support for TruTrace StrainSecure 2.0 for Next Generation Cannabis Tagging, Testing and Tracking - Seite 2

TruTrace’s blockchain-based SaaS software is designed to guarantee product quality and strain genetics throughout global supply chains. Protecting consumers and brands from contaminants and counterfeiting is a key benefit of the platform.

Robert Galarza, CEO of TruTrace, stated, “Over the past two years and after extensive work with key partners, such as Applied DNA, we’ve gained a deep understanding of the new challenges facing this industry. Version 2.0 of StrainSecure, as well as its interoperability with CertainT, will allow us to provide clients with turnkey tools specifically designed to support product quality, traceability, customer engagement, and safety.”

Most software systems utilized in the industry are fragmented and are built to manage internal operations, with very little interoperability into secondary systems. This fragmentation leads to increased administrative costs, reduced revenue, and increased risks for stakeholders. To address some of these issues, StrainSecure 2.0 will include several robust features tailored to decrease administrative costs, increase revenue, scale business operations, and highlight product quality. StrainSecure 2.0 also includes a significant number of new features, including full integration into the CertainT platform, that facilitate higher standards and fuels business growth. One such new feature is the Enhanced Scan Page, which serves as a marketing tool for brands by providing real-time data on products at the package level.

Galarza added, “The expectations of customers, as it relates to the quality of the products they choose to consume, has never been higher. StrainSecure 2.0 focuses on promoting good actors in the industry and giving them a solution, which unifies their network, mitigates risk, ensures compliance with commercial standards, and creates a safer and more consistent marketplace for their customers. Globally focused hemp and cannabis businesses equip themselves with StrainSecure to scale their business.”

About Applied DNA Sciences

Applied DNA is commercializing LinearDNA, its proprietary, large-scale polymerase chain reaction (“PCR”)-based manufacturing platform that allows for the large-scale production of specific DNA sequences.

The LinearDNA platform has utility in the nucleic acid-based in vitro diagnostics and preclinical nucleic acid-based drug development and manufacturing market. The platform is used to manufacture DNA for customers as components of in vitro diagnostic tests and for preclinical nucleic acid-based drug development in the fields of adoptive cell therapies (CAR T and TCR therapies), DNA vaccines (anti-viral and cancer), RNA therapies, clustered regularly interspaced short palindromic repeats (CRISPR) based therapies, and gene therapies. Applied DNA has also established a COVID-19 diagnostic and testing offering that is in the early stages of commercialization and is grounded in the Company’s deep expertise in DNA.